Department researchers are developing
new vaccines against these viruses and in identifying small molecular weight compounds for use as antivirals.
Not exact matches
Together with researchers at the CNRS, the group has demonstrated the efficacy of RNA - based
vaccines produced using the
new method
against plant
virus infections.
«It was not known whether any of these
vaccines could provide protection against the new outbreak West African Makona strain of Ebola Zaire currently circulating in Guinea,» said John Eldridge, Chief Scientific Officer - Vaccines at Profectus Biosciences, Inc. «Our findings show that our candidate vaccines provided complete, single dose protection from a lethal amount of the Makona strain of Ebola virus
vaccines could provide protection
against the
new outbreak West African Makona strain of Ebola Zaire currently circulating in Guinea,» said John Eldridge, Chief Scientific Officer -
Vaccines at Profectus Biosciences, Inc. «Our findings show that our candidate vaccines provided complete, single dose protection from a lethal amount of the Makona strain of Ebola virus
Vaccines at Profectus Biosciences, Inc. «Our findings show that our candidate
vaccines provided complete, single dose protection from a lethal amount of the Makona strain of Ebola virus
vaccines provided complete, single dose protection from a lethal amount of the Makona strain of Ebola
virus.»
The method is relatively
new, but far bacteria - based
vaccines have proven effective: A seasonal flu
vaccine produced by VaxInnate successfully protected humans in clinical trials, and the company's recently tested swine flu
vaccine immunized mice
against the
virus.
Understanding what combination of mutations could transform H5N1 into a human pandemic
virus gives epidemiologists a leg up on preparing countermeasures; they can, for example, test existing
vaccines against the
new strain.
The
new «trivalent»
vaccine induces antibodies
against three different parts of the
virus, including two components that normally help HSV2 evade immune attack.
The first live - attenuated Zika
vaccine still in the development stage completely protected mice
against the
virus after a single vaccination dose, according to
new research from The University of Texas Medical Branch at Galveston and Instituto Evandro Chagas at the Ministry of Health in Brazil.
Johns Hopkins Bloomberg School of Public Health researchers say a
new candidate
vaccine against respiratory syncytial
virus (RSV) made with a weakened version of the
virus shows great promise at fighting the disease, the leading cause of hospitalization for children under the age of one in the U.S.
The
new vaccine could arrive too late, not reach enough people, or not defend
against the circulating
virus for the following reasons:
«
Vaccine against respiratory syncytial
virus shows promise in early trial: Researchers describe a
new approach to developing RSV
vaccines, reporting promising early results in young children.»
An experimental
vaccine against the MERS
virus triggers immune protection, a
new study finds.
LONDON (Reuters)-- Researchers announced the launch of two big studies in Africa on Thursday to test a
new HIV
vaccine and a long - acting injectable drug, fuelling hopes for better ways to protect
against the
virus that causes AIDS.
A
vaccine that protects
against the
virus that causes Middle East respiratory syndrome (MERS) has been shown to be effective in camels, a
new study finds.
When flu researchers learned about this
new sugar - adorned H3N2
virus in 2014, they made sure to include that strain in the 2016 — 17 seasonal flu
vaccine so that immunized individuals would mount an immune response
against it.
In a previously published paper, Barouch and colleagues, including Colonel Nelson L. Michael, MD, PhD, director of the Military HIV Research Program at the Walter Reed Army Institute of Research (WRAIR) and Stephen Thomas, MD, Upstate Medical University, State University of
New York, demonstrated that three different
vaccine candidates provided robust protection
against Zika
virus in both mice and rhesus monkeys.
A
new study led by scientists at Beth Israel Deaconess Medical Center (BIDMC) shows that an HIV - 1
vaccine regimen, involving a viral vector boosted with a purified envelope protein, provided complete protection in half of the vaccinated non-human primates (NHPs)
against a series of six repeated challenges with simian immunodeficiency
virus (SIV), a
virus similar to HIV that infects NHPs.
Now they have created a
new hybrid
virus, part West Nile and part dengue, that shows promise as a
vaccine against West Nile
virus in mice.
The
new vaccine is the first to provide immunity
against the real - world
virus made famous by the film Contagion
Some of them have also been linked to human type 1 diabetes raising the possibility of developing
vaccines against these
viruses to prevent some of the
new cases of type 1 diabetes.
This
new discovery, funded by multiple groups, opens up novel possibilities for future research aimed at developing
vaccines against these
viruses to prevent type 1 diabetes.
«To date, neither antiviral drugs nor
vaccines are approved for clinical use
against human parainfluenza
virus, which reinforces the urgent need for
new therapeutic discovery strategies.
In this study, a total of 40 participants received GLS - 5700, the
new vaccine,
against two proteins of the Zika
virus.
But because these human strains frequently mutate to adapt to their
new environment in eggs, the resulting
vaccine is often an imperfect match to the actual
virus that it is supposed to protect
against.
This includes utilizing a modified chimpanzee
virus as a
vaccine carrier to induce an immune response
against HIV, and a
new therapeutic
vaccine against human papillomavirus (HPV), a leading cause of cervical cancer.
The
new Ad26 / MVA and Ad35 / Ad26 vector - based
vaccine regimens resulted in over 80 % reduction in the per - exposure probability of acquisition of infection
against repetitive challenges of SIV, a
virus similar to HIV that infects monkeys.
A
new generation DNA - based
vaccine against Zika
virus showed protection from infection, brain damage and death in a preclinical model.
This suggests that elder be superior to
vaccines in preventing flu, because flu
vaccines are only effective
against known strains of flu, whereas the
virus is continually mutating to
new strains.»
The
new bivalent
vaccine helps protect dogs
against the two strains of the
virus known to be circulating in the U.S., CIV H3N2 and CIV H3N8.
Zoetis Inc. has started shipping Vanguard CIV H3N2 / H3N8, the company's
newest vaccine against canine influenza
virus.
First, while certainly anyone (ferret, person, or other animal) can have a reaction to a
vaccine, the incidence of
vaccine reactions has dramatically decreased since
newer brands of
vaccine against both rabies and distemper
virus have been developed for ferrets and since we started administering a Benadryl injection just prior to giving the shots.
If you give that puppy the distemper
virus vaccine, it will neutralize some of the existing immunity
against the
virus, leaving the animal vulnerable until the
new antibodies from the
vaccine take over.